

# Stephen L Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1915821/publications.pdf>

Version: 2024-02-01

254  
papers

18,919  
citations

25034

57  
h-index

14208

128  
g-index

261  
all docs

261  
docs citations

261  
times ranked

18043  
citing authors

#	ARTICLE	IF	CITATIONS
1	Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 573-584.	7.3	18
2	Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥10cm) in Tumour Response and Long-Term Survival Outcome. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 172-181.	2.0	7
3	Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. <i>Cancer Letters</i> , 2022, 525, 115-130.	7.2	19
4	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 379-379.	1.6	235
5	CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. <i>Molecular Cancer</i> , 2022, 21, 10.	19.2	35
6	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1526.	3.7	7
7	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	2.8	43
8	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	7.0	32
9	Sarcoplasmic reticulum calcium handling in unbranched, immediately post-necrotic fast-twitch fibres is similar to wild-type littermates. <i>Experimental Physiology</i> , 2022, , .	2.0	0
10	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1197-1206.	2.8	13
11	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. <i>Clinical Chemistry</i> , 2022, 68, 1151-1163.	3.2	22
12	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	17
13	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
14	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. <i>Liver Cancer</i> , 2022, 11, 426-439.	7.7	11
15	Combined 18F-FDG and 11C-acetate positron emission tomography/computed tomography in staging and treatment decision in patients with hepatocellular carcinoma: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16176-e16176.	1.6	0
16	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 451-459.	7.7	3
17	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. <i>Cancers</i> , 2022, 14, 3213.	3.7	10
18	Immune Checkpoint Inhibitor-induced Enterocolitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, e70.	4.4	0

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	4.1	20
20	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31
21	Hyperprogression in hepatocellular carcinoma: Illusion or reality?. <i>Journal of Hepatology</i> , 2021, 74, 269-271.	3.7	9
22	Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1005-1015.	10.5	23
23	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
24	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021, 10, 107-114.	7.7	66
25	ALBI score and outcomes in patients with hepatocellular carcinoma: a post hoc analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	3.2	7
26	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. <i>ELife</i> , 2021, 10, .	6.0	19
27	Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. <i>JHEP Reports</i> , 2021, 3, 100224.	4.9	12
28	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	59
29	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1375-1382.	2.6	20
30	Management of Gastrointestinal Side Effects of Immune Checkpoint Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2262-2265.	4.4	2
31	Dystrophin-negative slow-twitch soleus muscles are not susceptible to eccentric contraction induced injury over the lifespan of the mdx mouse. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C704-C720.	4.6	11
32	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021, 67, 1492-1502.	3.2	9
33	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
34	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	2.4	9
35	Genome-wide detection of cytosine methylation by single molecule real-time sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	65
36	Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study. <i>Journal of Clinical Oncology</i> , 2021, 39, 272-272.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 510-521.	7.7	23
38	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. <i>Journal of Hepatology</i> , 2021, , .	3.7	3
39	Abstract PO-006: CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. , 2021, , .		0
40	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 365-379.	12.1	117
41	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
42	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
43	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	7.7	28
44	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020, 6, 1461-1471.	1.8	44
45	Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. <i>Liver Cancer</i> , 2020, 9, 491-502.	7.7	47
46	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14
47	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10705-10713.	3.6	5
48	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	5.5	61
49	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	4.5	51
50	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
51	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	7.7	172
52	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
53	Microbiome and cancer treatment: Are we ready to apply in clinics?. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 171, 301-308.	1.7	9
54	Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). <i>Hpb</i> , 2020, 22, 1121-1127.	0.3	40

#	ARTICLE	IF	CITATIONS
55	Contaminated and misidentified cell lines commonly use in cancer research. <i>Molecular Carcinogenesis</i> , 2020, 59, 573-574.	2.7	6
56	CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. <i>Cancer Research</i> , 2020, 80, 2138-2149.	0.9	106
57	Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2020, 477, 1-9.	7.2	20
58	Endoscopic ultrasoundâ€guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2192-2201.	2.8	2
59	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	7.0	58
60	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	3.7	310
61	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
62	Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 518-518.	1.6	15
63	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2020, 38, 528-528.	1.6	1
64	Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 522-522.	1.6	0
65	IDDF2020-ABS-0215â€...Enhancer reprogramming by selective HDAC8 inhibition potentiates tumor remission and durable benefit by PD-L1 blockade. , 2020, , .		0
66	Biology and significance of alphaâ€fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	3.9	327
67	Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. <i>Annals of Oncology</i> , 2019, 30, iv135-iv136.	1.2	10
68	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
69	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2019, 157, 1630-1645.e6.	1.3	123
70	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	5.5	16
71	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. <i>Nutrition and Cancer</i> , 2019, 71, 954-970.	2.0	7
72	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. <i>Quality of Life Research</i> , 2019, 28, 2597-2607.	3.1	4

#	ARTICLE	IF	CITATIONS
73	The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterology, 2019, 19, 66.	2.0	21
74	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Letters, 2019, 457, 98-109.	7.2	40
75	<p>Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mBI in patients with hepatocellular carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 2719-2727.	1.9	8
76	Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma. Cancer Research, 2019, 79, 1305-1317.	0.9	31
77	Systemic treatment of pancreatic neuroendocrine tumors. Surgical Practice, 2019, 23, 48-58.	0.2	0
78	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Research, 2019, 29, 418-427.	5.5	159
79	IDDF2019-ABS-0325â€¦Superior efficacy and long-term survival benefit of HDAC8 and PD-L1 co-blockade in liver cancer immunotherapy. , 2019, , .		0
80	IDDF2019-ABS-0174â€¦Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. , 2019, , .		0
81	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988900.	3.2	44
82	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	9.4	157
83	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 4004-4004.	1.6	149
84	Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.. Journal of Clinical Oncology, 2019, 37, 4088-4088.	1.6	19
85	Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 423-423.	1.6	7
86	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 40-54.	7.7	24
87	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. Hpb, 2018, 20, 546-554.	0.3	36
88	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Radiology, 2018, 287, 340-348.	7.3	4
89	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. British Journal of Cancer, 2018, 118, 248-257.	6.4	71
90	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Journal of the Royal College of Surgeons of Edinburgh, 2018, 16, 163-170.	1.8	21

#	ARTICLE	IF	CITATIONS
91	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 89-89.	3.0	30
92	IDDF2018-ABS-0229...Enhancing the efficacy of liver cancer immunotherapy by specific inhibition of histone deacetylase 8. , 2018, , .		0
93	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 524-530.	1.3	4
94	Reply to "Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma": <i>British Journal of Cancer</i> , 2018, 119, 781-782.	6.4	0
95	Gene embedding: A novel machine learning approach to identify gene candidates related to immunotherapy responsiveness. <i>Annals of Oncology</i> , 2018, 29, viii22.	1.2	1
96	ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. <i>Cell Death and Disease</i> , 2018, 9, 852.	6.3	15
97	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	10.7	1,816
98	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	27.0	1,677
99	Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. <i>Theranostics</i> , 2018, 8, 1740-1751.	10.0	80
100	A statistical model for survival risk prediction in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>Journal of Hepatology</i> , 2018, 68, S197-S198.	3.7	0
101	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1436-1445.	3.7	9
102	Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery. <i>Frontiers in Genetics</i> , 2018, 9, 682.	2.3	29
103	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4020-4020.	1.6	9
104	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4088-4088.	1.6	6
105	A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4144-TPS4144.	1.6	73
106	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	1.6	62
107	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 209-209.	1.6	30
108	Abstract 4563: PD-L1 expression associated with treatment responses in colorectal cancer patients with XELOX/FOLFOX chemotherapy: Potential of checkpoint blockage and natural killer cell-based immunotherapy. , 2018, , .		1



#	ARTICLE	IF	CITATIONS
109	Incorporating albuminâ€“bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 221-228.	2.8	47
110	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017, 116, 441-447.	6.4	46
111	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma â€“ clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , 2017, 17, 8.	2.6	38
112	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	6.4	66
113	Validating the ALBI grade: Its current and future use in HCC prognostication. <i>Journal of Hepatology</i> , 2017, 66, 661-663.	3.7	11
114	Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. <i>Journal of Hepatology</i> , 2017, 66, S620-S621.	3.7	1
115	Analysis of Plasma Epsteinâ€“Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 513-522.	27.0	531
116	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	4.1	22
117	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 280-289.	3.9	38
118	Liver stiffness measurement predicts highâ€“grade postâ€“hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.8	39
119	Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC). <i>Annals of Oncology</i> , 2017, 28, x112.	1.2	0
120	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2017, , 623-635.	0.1	3
121	Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression. <i>Cancer Research</i> , 2017, 77, CT106-CT106.	0.9	16
122	Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4143-TPS4143.	1.6	3
123	A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 262-262.	1.6	1
124	KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS503-TPS503.	1.6	29
125	KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS504-TPS504.	1.6	8
126	Epidemiology of lung cancer: A joinpoint analysis of temporal incidence and mortality trends in 38 countries.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13091-e13091.	1.6	0



#	ARTICLE	IF	CITATIONS
127	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15679-e15679.	1.6	0
128	Abstract 1241: A preclinical study of the combined treatment of arginase and canavanine in pancreatic cancer. , 2017, , .		0
129	Abstract 5059: Preclinical study on the efficacy of Panobinostat in hepatocellular carcinoma. , 2017, , .		0
130	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World Journal of Gastroenterology, 2016, 22, 7289.	3.3	138
131	Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation. Annals of Oncology, 2016, 27, vi332.	1.2	0
132	Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study. Annals of Oncology, 2016, 27, vi241.	1.2	4
133	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British Journal of Cancer, 2016, 114, 744-750.	6.4	150
134	Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 789-802.	3.3	16
135	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clinical Gastroenterology and Hepatology, 2016, 14, 875-886.e6.	4.4	217
136	Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients". European Journal of Cancer, 2016, 68, 203-205.	2.8	0
137	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology, 2016, 69, 971-984.	2.9	21
138	Circulating Neutrophils " Immunological Drivers of Hepatocellular Carcinoma Progression?. Journal of Hepatology, 2016, 64, S323.	3.7	0
139	Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade. Journal of Hepatology, 2016, 64, S693-S694.	3.7	1
140	What do oncologists need to know about biosimilar products?. Chinese Journal of Cancer, 2016, 35, 91.	4.9	10
141	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1766-1772.	2.8	47
142	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 289-295.	3.7	89
143	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology, 2016, 64, 774-784.	7.3	77
144	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1300-1306.	2.8	103

#	ARTICLE	IF	CITATIONS
145	Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 639-649.	0.5	6
146	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-90.	1.6	131
147	Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , 2016, 45, 77-86.	7.7	51
148	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3566-3566.	1.6	1
149	A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4074-4074.	1.6	5
150	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3103-TPS3103.	1.6	5
151	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2016, , 1-13.	0.1	0
152	2244 Integration of Albumin-Bilirubin (ALBI) score into current tumour staging system for hepatocellular carcinoma (HCC). <i>European Journal of Cancer</i> , 2015, 51, S414.	2.8	0
153	Clinical utility of plasma Epstein-Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	4.1	43
154	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1529-1535.	2.8	14
155	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
156	Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma. <i>Current Gene Therapy</i> , 2015, 15, 97-108.	2.0	8
157	Phase I/II study of tlemsirrolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	2.6	96
158	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1224-1235.	4.1	74
159	SIRT-Y90 followed by gemcitabine plus cisplatin for Intra-hepatic cholangiocarcinoma: a phase II study. <i>Annals of Oncology</i> , 2015, 26, vii121.	1.2	0
160	Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2015, 26, 2457-2463.	1.2	85
161	Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. <i>EBioMedicine</i> , 2015, 2, 497-498.	6.1	0
162	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1317-25.	7.1	543

#	ARTICLE	IF	CITATIONS
163	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	1.6	1,810
164	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	1.5	206
165	Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 51-69.	7.7	43
166	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	3.4	9
167	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	3.7	66
168	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , 2015, 47, 178-181.	0.6	11
169	Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5503-12.	7.1	579
170	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6031-6031.	1.6	2
171	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 237-237.	1.6	5
172	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4073-4073.	1.6	0
173	Drug Development for Hepatocellular Carcinoma: Knowing the Past Helps to Understand the Future. <i>Oncologist</i> , 2014, 19, 1115-1117.	3.7	8
174	Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. <i>Radiology</i> , 2014, 270, 607-620.	7.3	44
175	Economic analysis of aprepitant—containing regimen to prevent chemotherapy—induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in <sc>H</sc>ong <sc>K</sc>ong. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 80-91.	1.1	18
176	Performance of serum Î±-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. <i>Hpb</i> , 2014, 16, 366-372.	0.3	48
177	A Small-Molecule Modulator of the Tumor-Suppressor miR34a Inhibits the Growth of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2014, 74, 6236-6247.	0.9	86
178	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1607-1614.	3.3	10
179	Expression of stemness markers (<sc>CD</sc>133 and Ep<sc>CAM</sc>) in prognostication of hepatocellular carcinoma. <i>Histopathology</i> , 2014, 64, 935-950.	2.9	75
180	623: Efficacy of temsirolimus for advanced hepatocellular carcinoma (HCC) - assessment of pS6 as potential prognostic biomarker of response. <i>European Journal of Cancer</i> , 2014, 50, S148.	2.8	0

#	ARTICLE	IF	CITATIONS
181	Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. Journal of Clinical Oncology, 2014, 32, 4094-4094.	1.6	3
182	Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC;). Tj ETQq0 0 0 rgBT /Overlook 10 Tf 505697 Td (f	1.6	1
183	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. Journal of Clinical Oncology, 2014, 32, 6029-6029.	1.6	1
184	Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World Journal of Gastroenterology, 2014, 20, 3135.	3.3	13
185	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese Journal of Cancer, 2014, 33, 267-276.	4.9	17
186	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chinese Journal of Cancer, 2014, 33, 481-91.	4.9	22
187	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. Journal of Clinical Oncology, 2014, 32, 181-181.	1.6	0
188	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 1417-1425.	2.3	12
189	Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. Gastroenterology, 2013, 144, 1086-1097.e9.	1.3	57
190	Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 211-224.	3.2	447
191	RE: Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. Journal of the National Cancer Institute, 2013, 105, 580-580.	6.3	0
192	Targeted therapy for hepatocellular carcinoma: current status and future direction. Clinical Investigation, 2013, 3, 83-93.	0.0	0
193	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Research, 2013, 73, 1676-1688.	0.9	159
194	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18761-18768.	7.1	363
195	Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 2-5.	1.1	4
196	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. International Journal of Hepatology, 2013, 2013, 1-10.	1.1	20
197	Intermittent versus continuous erlotinib with concomitant modified XELOX (q3W) in first-line treatment of metastatic colorectal cancer. Cancer, 2013, 119, 4145-4153.	4.1	11
198	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).. Journal of Clinical Oncology, 2013, 31, 425-425.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. <i>Hong Kong Medical Journal</i> , 2013, 19, 407-15.	0.1	6
200	A phase II study of concurrent cetuximab+ cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012, 23, 1287-1292.	1.2	111
201	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2012, 104, 300-304.	0.6	93
202	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
203	Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S63-S68.	3.4	19
204	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 3984-3992.	4.1	53
205	Management of Hepatocellular Carcinoma: Beyond Sorafenib. <i>Current Oncology Reports</i> , 2012, 14, 257-266.	4.0	27
206	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
207	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	4.4	28
208	Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: An Asian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 111-114.	1.1	2
209	Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 74-75.	3.7	2
210	Targeted therapy of hepatocellular carcinoma: Present and future. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 862-872.	2.8	72
211	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 259-259.	1.6	1
212	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
213	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14528-e14528.	1.6	0
214	Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right population. <i>Chinese Clinical Oncology</i> , 2012, 1, 8.	1.2	0
215	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma " a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). <i>European Journal of Cancer</i> , 2011, 47, S470-S471.	2.8	3
216	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 340-347.	2.8	75

#	ARTICLE	IF	CITATIONS
217	P282 The menopausal status of young Chinese women with early stage breast cancer after adjuvant chemotherapy. <i>Breast</i> , 2011, 20, S68.	2.2	0
218	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 539-545.	2.3	29
219	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , 2011, 22, 1280-1287.	1.2	102
220	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2592-2592.	1.6	2
221	The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5532-5532.	1.6	1
222	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 205-205.	1.6	1
223	Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4058-4058.	1.6	0
224	Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. <i>Hong Kong Medical Journal</i> , 2011, 17, 112-8.	0.1	12
225	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	2.6	56
226	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2409-2414.	2.3	8
227	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
228	Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. <i>Contemporary Clinical Trials</i> , 2010, 31, 135.	1.8	1
229	560 OBSTETRIC HISTORY AND THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN FEMALE CHRONIC HEPATITIS B CARRIERS. <i>Journal of Hepatology</i> , 2010, 52, S223.	3.7	0
230	PARP inhibition in BRCA-mutated breast and ovarian cancers. <i>Lancet, The</i> , 2010, 376, 211-213.	13.7	49
231	Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2585-2585.	1.6	3
232	The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4028-4028.	1.6	0
233	Reply to L.-T. Chen et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e272-e272.	1.6	1
234	New Utility of an Old Marker: Serial $\alpha$ -Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 446-452.	1.6	241



#	ARTICLE	IF	CITATIONS
235	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , 2009, 20, 1854-1859.	1.2	55
236	0150 The severity of chemotherapy-induced neutropenia in association with PTGS-2 gene polymorphism in breast cancer patients. <i>Breast</i> , 2009, 18, S57.	2.2	0
237	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , 2009, 124, 644-652.	5.1	192
238	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 529-535.	2.5	74
239	Lymphedema and quality of life in Chinese women after treatment for breast cancer. <i>European Journal of Oncology Nursing</i> , 2009, 13, 110-115.	2.1	42
240	Role of $\alpha$ -fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , 2009, 5, 889-899.	2.4	30
241	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
242	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2008, 26, 3052-3052.	1.6	2
243	Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- Prospective validation of the Chinese University Prognostic Index. <i>Journal of Clinical Oncology</i> , 2008, 26, 4591-4591.	1.6	1
244	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2008, 26, 6055-6055.	1.6	12
245	Serial alpha-feto protein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 4602-4602.	1.6	0
246	Dose-volume analysis of radiation dermatitis among nasopharyngeal carcinoma patients treated with concurrent cetuximab-cisplatin and intensity-modulated radiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 17015-17015.	1.6	0
247	Accomplishments in 2007 in the management of hepatobiliary cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S25-31.	0.7	5
248	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , 2007, 45, 1382-1389.	7.3	60
249	The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. <i>Laboratory Investigation</i> , 2007, 87, 644-650.	3.7	93
250	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2006, 6, 259.	2.6	7
251	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , 2006, 17, 1083-1089.	1.2	99
252	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , 2006, 61, 182-182.	5.6	3



#	ARTICLE	IF	CITATIONS
253	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta Oncologica</i> , 2005, 44, 177-179.	1.8	2
254	Misleading chest radiography in a patient with SARS. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 318-319.	1.5	2